Reviews of Infectious Diseases

Volume 5 • Number 1 • January–February 1983

REVIEW ARTICLES

Tracy L. Gustafson, Jeffrey D. Band, Robert H. Hutcheson, Jr., and William Schaffner	Pseudomonas Folliculitis: An Outbreak and Review	1
Joseph G. Sinkovics and Gordon R. Dreesman	Monoclonal Antibodies of Hybridomas	9
Melvin P. Weinstein, L. Barth Reller, James R. Murphy, and Kenneth A. Lichtenstein	The Clinical Significance of Positive Blood Cultures: A Comprehensive Analysis of 500 Episodes of Bacteremia and Fungemia in Adults. I. Laboratory and Epidemiologic Observations	35
Melvin P. Weinstein, James R. Murphy, L. Barth Reller, and Kenneth A. Lichtenstein	The Clinical Significance of Positive Blood Cultures: A Comprehensive Analysis of 500 Episodes of Bacteremia and Fungemia in Adults. II. Clinical Observations, with Special Reference to Factors Influencing Prognosis	54
Heikki Peltola	Meningococcal Disease: Still with Us	71
Alfred M. Prince, Wolfgang Stephan, and Betsy Brotman	β-Propiolactone/Ultraviolet Irradiation: A Review of Its Effectiveness for Inactivation of Viruses in Blood Derivatives	92
Stephen A. Berger, Joel Zonszein, Patricia Villamena, and Neal Mittman	Infectious Diseases of the Thyroid Gland	108
Richard J. Wallace, Jr., Carol J. Baker, Frank J. Quinones, Dannie G. Hollis, Robert E. Weaver, and Karen Wiss	Nontypable *Haemophilus influenzae* (Biotype 4) as a Neonatal, Maternal, and Genital Pathogen	123
Barrett Sugarman	Zinc and Infection	137

HISTORICAL ARTICLE

Eli Chernin	Sir Patrick Manson's Studies on the Transmission and Biology of Filariasis	148

CORRESPONDENCE

Philip A. Mackowiak and James W. Smith	Polymicrobial Infections in Osteomyelitis	167
Michael E. Pichichero	Reply	168

NOTICE 169

REVIEWERS FOR VOLUME 4 170

STATEMENT OF EDITORIAL POLICY AND INSTRUCTIONS TO AUTHORS 172

Volume 5 • Number 2 • March–April 1983

REVIEW ARTICLES

FRANK J. BIA, BRIGITTE P. GRIFFITH, CAROLINE K. Y. FONG, AND G. D. HSIUNG — Cytomegaloviral Infections in the Guinea Pig: Experimental Models for Human Disease 177

R. AUCKENTHALER, P. E. HERMANS, AND J. A. WASHINGTON II — Group G Streptococcal Bacteremia: Clinical Study and Review of the Literature 196

M. COLIN JORDAN — Latent Infection and the Elusive Cytomegalovirus 205

ISRAEL H. LICHTENSTEIN AND ROB ROY MACGREGOR — Mycobacterial Infections in Renal Transplant Recipients: Report of Five Cases and Review of the Literature 216

ROBERT PARSONS, JAY GREGORY, AND DARWIN L. PALMER — Salmonella Infections of the Abdominal Aorta 227

INFECTIOUS DISEASES UPDATE: 1982
EXCERPTS FROM A SYMPOSIUM

GERALD P. BODEY — Summary of the Symposium 232

JOHN G. BARTLETT — Recent Developments in the Management of Anaerobic Infections 235

ROBERT FEKETY — Recent Advances in Management of Bacterial Diarrhea 246

RICHARD MEYER — Legionella Infections: A Review of Five Years of Research 258

GERALD P. BODEY, RICARDO BOLIVAR, VICTOR FAINSTEIN, AND LEENA JADEJA — Infections Caused by *Pseudomonas aeruginosa* 279

MILAGROS P. REYES AND A. MARTIN LERNER — Current Problems in the Treatment of Infective Endocarditis Due to *Pseudomonas aeruginosa* 314

SERIAL FEATURES

DONALD P. FRANCIS — Selective Primary Health Care: Strategies for Control of Disease in the Developing World. III. Hepatitis B Virus and Its Related Diseases 322

JULIA A. WALSH — Selective Primary Health Care: Strategies for Control of Disease in the Developing World. IV. Measles 330

HYPOTHESES

ELLIOT J. RAYFIELD AND STEPHEN J. MENTO — Viruses May Be Etiologic Agents for Non-Insulin-Dependent (Type II) Diabetes — 341

T. PANG — Delayed-type Hypersensitivity: Probable Role in the Pathogenesis of Dengue Hemorrhagic Fever/Dengue Shock Syndrome — 346

HISTORICAL ARTICLE

ELI CHERNIN — Sir Patrick Manson: An Annotated Bibliography and a Note on a Collected Set of His Writings — 353

NOTICE — 387

Volume 5 • Supplement 1 • March–April 1983

Participants — vi

JEROME O. KLEIN AND HAROLD C. NEU — Preface — S1

KEYNOTE ADDRESS

MAXWELL FINLAND — Empiric Therapy for Bacterial Infections: The Historical Perspective — S2

SESSION I: EMPIRIC THERAPY FOR BACTERIAL INFECTIONS

HAROLD C. NEU — The Emergence of Bacterial Resistance and Its Influence on Empiric Therapy — S9

J. KLASTERSKY — Empiric Treatment of Infections in Neutropenic Patients with Cancer — S21

JAMES D. CHERRY — Selection of Antimicrobial Agents for Initial Treatment of Suspected Septicemia in Infants and Children — S32

GERALD R. DONOWITZ AND GERALD L. MANDELL — Empiric Therapy for Pneumonia — S40

Discussion — S52

JEROME O. KLEIN, BARRY DASHEFSKY, CHRISTINE R. NORTON, AND JULIE MAYER — Selection of Antimicrobial Agents for Treatment of Neonatal Sepsis — S55

Discussion — S63

RICHARD PLATT — Diagnosis and Empiric Therapy of Urinary Tract Infection in the Seriously Ill Patient — S65

WILLIAM R. MCCABE — Empiric Therapy for Bacterial Meningitis — S74

Vera L. Sutter	Frequency of Occurrence and Antimicrobial Susceptibility of Bacterial Isolates from the Intestinal and Female Genital Tracts	S84
Ronald Lee Nichols	Empiric Antibiotic Therapy for Intraabdominal Infections	S90
William J. Ledger	Selection of Antimicrobial Agents for Treatment of Infections of the Female Genital Tract	S98
	Discussion	S105
	SESSION II: EVALUATION OF CEFOPERAZONE	
Ronald N. Jones and Arthur L. Barry	Cefoperazone: A Review of Its Antimicrobial Spectrum, β-Lactamase Stability, Enzyme Inhibition, and Other in Vitro Characteristics	S108
Ronald A. Greenfield, Andreas U. Gerber, and William A. Craig	Pharmacokinetics of Cefoperazone in Patients with Normal and Impaired Hepatic and Renal Function	S127
William G. Gardner	Multicentered Clinical Evaluation of Cefoperazone for the Treatment of Lower Respiratory Tract Infections	S137
Thomas M. File, Jr. and James S. Tan	Cefoperazone for the Treatment of Acute Urinary Tract Infection: Multicentered Comparative and Noncomparative Studies	S145
Larry J. Strausbaugh and Alfred S. Llorens	Cefoperazone Therapy for Obstetric and Gynecologic Infections	S154
E. William Rosenberg	Use of Cefoperazone in the Empiric Treatment of Serious Skin Infections	S161
Ian M. Baird	Multicentered Study of Cefoperazone for Treatment of Intraabdominal Infections and Comparison of Cefoperazone with Cefamandole and Clindamycin plus Gentamicin for Treatment of Appendicitis and Peritonitis	S165
John W. Warren, E. Huxley Miller, Jr., Brian Fitzpatrick, Diane E. DiFranco, Ellis S. Caplan, James H. Tenney, and William C. Anthony	A Randomized, Controlled Trial of Cefoperazone vs. Cefamandole-Tobramycin in the Treatment of Putative, Severe Infections with Gram-Negative Bacilli	S173
Ricardo Bolivar, Victor Fainstein, Linda Elting, and Gerald P. Bodey	Cefoperazone for the Treatment of Infections in Patients with Cancer	S181
A. J. Gordon and M. Phyfferoen	Cefoperazone Sodium in the Treatment of Serious Bacterial Infections in 2,100 Adults and Children: Multicentered Trials in Europe, Latin America, and Australasia	S188
S. A. Gall and G. Hill	Cefoperazone as a Prophylactic Agent in Abdominal Hysterectomy	S200
	Discussion	S202

Volume 5 • Number 3 • May–June 1983

	Participants	vi
Saul Krugman, Samuel L. Katz, and Thomas C. Quinn	Preface	389
	SESSION I: CURRENT IMPACT OF MEASLES	
Pap J. Williams and Harry F. Hull	Status of Measles in The Gambia, 1981	391
Ronald O. C. Kaschula, Jennifer Druker, and Arthur Kipps	Late Morphologic Consequences of Measles: A Lethal and Debilitating Lung Disease Among the Poor	395
Eddy K. C. Lo and Nafisah bt. AliHussein	Measles in Malaysia: A Brief Report of the 1981 Anti-Measles Pilot Study	405
K. H. Dave	Measles in India	406
Zhang Yihao and Su Wannian	A Review of the Current Impact of Measles in the People's Republic of China	411
José Manuel Borgoño	Current Impact of Measles in Latin America	417
Jorge Fernandez de Castro	Measles in Mexico	422
Christine L. Miller	Current Impact of Measles in the United Kingdom	427
Michel Rey, Josette Celers, Yves Mouton, and Robert Netter	Impact of Measles in France	433
Alan R. Hinman, Walter A. Orenstein, Alan B. Bloch, Kenneth J. Bart, Donald L. Eddins, Robert W. Amler, and Cecil D. Kirby	Impact of Measles in the United States	439
R. P. Bryce Larke	Impact of Measles in Canada	445
F. Assaad	Measles: Summary of Worldwide Impact	452
David Morley	Severe Measles: Some Unanswered Questions	460
John P. Fox	Herd Immunity and Measles	463
John L. Sever	Persistent Measles Infection of the Central Nervous System: Subacute Sclerosing Panencephalitis	467
Alexander D. Langmuir and Walter Orenstein	Current Impact of Measles: Summary	474
	SESSION II: MEASLES VACCINES	
Saul Krugman	Further-Attenuated Measles Vaccine: Characteristics and Use	477

G. F. Mann, L. M. C. Allison, J. S. Lloyd, P. Tam, A. J. Zuckerman, and F. T. Perkins	Stability of Further-Attenuated Measles Vaccines	482
T. V. Peradze and A. A. Smorodintsev	Epidemiology and Specific Prophylaxis of Measles	487
H. Mirchamsy	Measles Immunization in Iran	491
Munehiro Hirayama	Measles Vaccines Used in Japan	495
Satoshi Makino	Development and Characteristics of Live AIK-C Measles Virus Vaccine: A Brief Report	504
Xiang Jianzhi and Chen Zhihui	Measles Vaccine in the People's Republic of China	506
Maurice R. Hilleman, William J. McAleer, Arlene A. McLean, Eugene B. Buynak, and Henry Z. Markus	Stabilized Measles Vaccine in a Novel Single-Dose Delivery System: A Practical Reality for Worldwide Elimination of Measles	511
Albert B. Sabin	Immunization Against Measles by Aerosol	514
Robert W. Amler, Walter A. Orenstein, and Kenneth J. Bart	Editorial: Aerosolized Measles Vaccine—Will It Open the Window?	524
S. Michael Peretz	Prospects for Future Supplies of Vaccines	527
Frank T. Perkins	Measles Vaccines: Discussion	531
F. E. André	Thermodegradation of Lyophilized Measles Vaccines	532
Paul D. Parkman and Robert W. Amler	Measles Vaccines: Summary	535
	SESSION III: CURRENT MEASLES CONTROL	
Alan R. Hinman, Cecil D. Kirby, Donald L. Eddins, Walter A. Orenstein, Roger H. Bernier, Paul M. Turner, and Kenneth J. Bart	Elimination of Indigenous Measles from the United States	538
Samuel Ofosu-Amaah	The Control of Measles in Tropical Africa: A Review of Past and Present Efforts	546
M. P. Mandara and J. Remme	Current Measles Control in Tanzania	554
Drago M. Ikić	Edmonston-Zagreb Strain of Measles Vaccine: Epidemiologic Evaluation in Yugoslavia	558
Jan Šejda	Control of Measles in Czechoslovakia (CSSR)	564
Zhang Yihao and Su Wannian	Introduction to the Control of Measles by Vaccination in the People's Republic of China	568
T. M. Pollock	Measles Control in the United Kingdom	574

Franklin M. M. White	Policy for Measles Elimination in Canada and Program Implications	577
João Baptista Risi, Jr.	Control of Measles in Brazil	583
Emilia M. León de Coto	Evolution of the Measles Vaccination Program in Costa Rica	588
Ralph H. Henderson	Primary Health Care as a Practical Means for Measles Control	592
Ministries of Health of Brazil, Chile, Costa Rica, and Ecuador and the Pan American Health Organization	Seroconversion Rates and Measles Antibody Titers Induced by Measles Vaccination in Latin American Children Six to 12 Months of Age	596
D. A. Henderson	Primary Health Care as a Practical Means for Measles Control: Discussion	606
J. Kostrzewski	Current Measles Control: Discussion	608
Karl A. Western and Paul M. Turner, Jr.	Current Measles Control: Summary	611
	SESSION IV: CONCLUSION	
William S. Jordan, Jr.	Measles Immunization: Remaining Needs for Research	613
Frederick C. Robbins	Prospects for Worldwide Control of Measles: Discussion I	619
John A. Dudgeon	Prospects for Worldwide Control of Measles: Discussion II	621
Samuel L. Katz	Summary of Current Status of Measles and Recommendations	623
Holger Lundbeck and Alan B. Bloch	Concluding Session: Summary	625
	NOTICES	626

Volume 5 • Supplement 2 • May–June 1983

	Participants	vi
David N. Gilbert and Jay P. Sanford	Preface	S211
	SESSION I: AMINOGLYCOSIDE ANTIBIOTICS: EFFICACY	
Robert C. Moellering, Jr.	In Vitro Antibacterial Activity of the Aminoglycoside Antibiotics	S212
	Discussion	S231

VINCENT T. ANDRIOLE	Aminoglycoside Antibiotics: Antibacterial Efficacy in Animal Models of Infection	S233
LOWELL S. YOUNG	Problems in Determining the Efficacy of Aminoglycosides	S250
	Discussion	S258
	SESSION II: AMINOGLYCOSIDE ANTIBIOTICS: RESISTANCE AND TOXICITY	
GEORGE GEE JACKSON	Aminoglycoside Antibiotics: Resistance and Toxicity—An Introduction	S260
JULIAN E. DAVIES	Resistance to Aminoglycosides: Mechanisms and Frequency	S261
	Discussion	S266
FRIEDRICH C. LUFT, WILLIAM H. BENNETT, AND DAVID N. GILBERT	Experimental Aminoglycoside Nephrotoxicity: Accomplishments and Future Potential	S268
PAUL S. LIETMAN AND CRAIG R. SMITH	Aminoglycoside Nephrotoxicity in Humans	S284
	Discussion	S292
ROBERT E. BRUMMETT	Animal Models of Aminoglycoside Antibiotic Ototoxicity	S294
WILLARD E. FEE, JR.	Gentamicin and Tobramycin: Comparison of Ototoxicity	S304
	Discussion	S312
GEORGE GEE JACKSON	Aminoglycoside Antibiotics: Resistance and Toxicity—A Summary	S314
	SESSION III: β-LACTAM ANTIBIOTICS: EFFICACY	
CALVIN M. KUNIN	β-Lactam Efficacy—Introduction	S317
HAROLD C. NEU	Structure-Activity Relations of New β-Lactam Compounds and in Vitro Activity Against Common Bacteria	S319
	Discussion	S337
JOHN G. BARTLETT, GEORGE J. R. MARIEN, MANOUCHEHR DEZFULIAN, AND KEITH A. JOINER	Relative Efficacy of β-Lactam Antimicrobial Agents in Two Animal Models of Infections Involving *Bacteroides fragilis*	S338
THOMAS A. DRAKE AND MERLE A. SANDE	Studies of the Chemotherapy of Endocarditis: Correlation of in Vitro, Animal Model, and Clinical Studies	S345
	Discussion	S354
	SESSION IV: β-LACTAM ANTIBIOTICS: RESISTANCE AND TOXICITY	
RICHARD B. SYKES AND KAREN BUSH	Interaction of New Cephalosporins with β-Lactamases and β-Lactamase-Producing Gram-Negative Bacilli	S356
	Discussion	S367

Andrew Saxon	Immediate Hypersensitivity Reactions to β-Lactam Antibiotics	S368
	Discussion	S379
Nils U. Bang and Robert B. Kammer	Hematologic Complications Associated with β-Lactam Antibiotics	S380
	Discussion	S393
	PANEL DISCUSSION: THE CLINICAL PERSPECTIVE	S394

Volume 5 • Number 4 • July–August 1983

REVIEW ARTICLES

Charles S. Bryan, Kenneth L. Reynolds, and Eric R. Brenner	Analysis of 1,186 Episodes of Gram-Negative Bacteremia in Non-University Hospitals: The Effects of Antimicrobial Therapy	629
Christine C. Sanders and W. Eugene Sanders, Jr.	Emergence of Resistance During Therapy with the Newer β-Lactam Antibiotics: Role of Inducible β-Lactamases and Implications for the Future	639
C. Cocito and J. Delville	Properties of Microorganisms Isolated from Human Leprosy Lesions	649
Richard J. Wallace, Jr., Jana M. Swenson, Vella A. Silcox, Robert C. Good, Jaime A. Tschen, and Mary Seabury Stone	Spectrum of Disease Due to Rapidly Growing Mycobacteria	657
Gary P. Wormser and Edward J. Bottone	*Cardiobacterium hominis:* Review of Microbiologic and Clinical Features	680
William C. Templeton III, Anthony Wawrukiewicz, Julio C. Melo, Martin G. Schiller, and Martin J. Raff	Anaerobic Osteomyelitis of Long Bones	692
E. Russell Alexander and H. Robert Harrison	Role of *Chlamydia trachomatis* in Perinatal Infection	713
	CLINICAL STUDIES OF INFLUENZA VACCINES—1978	
John R. La Montagne	Preface	722
John R. La Montagne, Gary R. Noble, Gerald V. Quinnan, George T. Curlin, William C. Blackwelder, Jacqueline I. Smith, Francis A. Ennis, and F. Marilyn Bozeman	Summary of Clinical Trials of Inactivated Influenza Vaccine—1978	723

Thomas R. Cate, Robert B. Couch, Donna Parker, and Barbara Baxter	Reactogenicity, Immunogenicity, and Antibody Persistence in Adults Given Inactivated Influenza Virus Vaccines—1978	737
Gerald V. Quinnan, Robert Schooley, Raphael Dolin, Francis A. Ennis, Peter Gross, and Jack M. Gwaltney	Serologic Responses and Systemic Reactions in Adults After Vaccination with Monovalent A/USSR/77 and Trivalent A/USSR/77, A/Texas/77, B/Hong Kong/72 Influenza Vaccines	748
Peter F. Wright, James D. Cherry, Hjordis M. Foy, W. Paul Glezen, Caroline B. Hall, Kenneth McIntosh, Arnold S. Monto, Robert H. Parrott, Bernard Portnoy, and Larry H. Taber	Antigenicity and Reactogenicity of Influenza A/USSR/77 Virus Vaccine in Children—A Multicentered Evaluation of Dosage and Safety	758
	SERIAL FEATURES	
Barry R. Bloom and Tore Godal	Selective Primary Health Care: Strategies for Control of Disease in the Developing World. V. Leprosy	765
Bruce M. Greene	Selective Primary Health Care: Strategies for Control of Disease in the Developing World. VI. Onchocerciasis	781
	CLASSICS IN INFECTIOUS DISEASES	
E. H. Derrick	"Q" Fever, a New Fever Entity: Clinical Features, Diagnosis and Laboratory Investigation	790
F. M. Burnet and Mavis Freeman	Experimental Studies on the Virus of "Q" Fever	800
	CORRESPONDENCE	
Daniel M. Musher	Antibiotics: The Medium Is the Message	809
	ERRATUM (Prince AM, Stephan W, Brotman B, 5:92–107)	813
	NOTICES	814
	STATEMENT OF EDITORIAL POLICY AND INSTRUCTIONS TO AUTHORS	816
	Volume 5 • Supplement 3 • July–August 1983	
	Participants	vi
	INTRODUCTION	
Merle A. Sande	The Use of Rifampin in the Treatment of Nontuberculous Infections: An Overview	S399

SESSION I

P. Sensi	History of the Development of Rifampin	S402
Walter Wehrli	Rifampin: Mechanisms of Action and Resistance	S407
Clyde Thornsberry, B. C. Hill, J. M. Swenson, and L. K. McDougal	Rifampin: Spectrum of Antibacterial Activity	S412
Victor Lorian, Barbara Atkinson, and Yehum Kim	Effect of Rifampin and Oxacillin on the Ultrastructure and Growth of *Staphylococcus aureus*	S418
Gianni Acocella	Pharmacokinetics and Metabolism of Rifampin in Humans	S428
Allan Weber, Kent E. Opheim, Arnold L. Smith, and Keith Wong	High-Pressure Liquid Chromatographic Quantitation of Rifampin and Its Two Major Metabolites in Urine and Serum	S433
Jacques Grosset and Stephanie Leventis	Adverse Effects of Rifampin	S440
George Gee Jackson	Summary	S447

SESSION II

Harry N. Beaty	Rifampin and Minocycline in Meningococcal Disease	S451
L. Joseph Wheat, Richard B. Kohler, Friedrich C. Luft, and Arthur White	Long-Term Studies of the Effect of Rifampin on Nasal Carriage of Coagulase-Positive Staphylococci	S459
Gerald L. Mandell	The Antimicrobial Activity of Rifampin: Emphasis on the Relation to Phagocytes	S463
C. O. Solberg, A. Haltensen, A. Digranes, and K. B. Hellum	Penetration of Antibiotics into Human Leukocytes and Dermal Suction Blisters	S468
K. Tshefu, W. Zimmerli, and F. A. Waldvogel	Short-Term Administration of Rifampin in the Prevention or Eradication of Infection Due to Foreign Bodies	S474
Oto Zak, W. Michael Scheld, and Merle A. Sande	Rifampin in Experimental Endocarditis Due to *Staphylococcus aureus* in Rabbits	S481
Carl W. Norden	Experimental Chronic Staphylococcal Osteomyelitis in Rabbits: Treatment with Rifampin Alone and in Combination with Other Antimicrobial Agents	S491
Carl W. Norden, Joshua Fierer, Richard E. Bryant, and the Chronic Staphylococcal Osteomyelitis Study Group	Chronic Staphylococcal Osteomyelitis: Treatment with Regimens Containing Rifampin	S495
J. F. Acar, F. W. Goldstein, and J. Duval	Use of Rifampin for the Treatment of Serious Staphylococcal and Gram-Negative Bacillary Infections	S502
Gwynn Lee Simon, Ronald H. Smith, and Merle A. Sande	Emergence of Rifampin-Resistant Strains of *Staphylococcus aureus* During Combination Therapy with Vancomycin and Rifampin: A Report of Two Cases	S507
P. Van Der Auwera and J. Klastersky	In Vitro Study of the Combination of Rifampin with Oxacillin Against *Staphylococcus aureus*	S509

P. Van Der Auwera, F. Meunier-Carpentier, and J. Klastersky	Clinical Study of Combination Therapy with Oxacillin and Rifampin for Staphylococcal Infections	S515
Natasha T. Hays, Warren E. Regelmann, and Paul G. Quie	The Use of Rifampin in Patients with Chronic Granulomatous Disease of Childhood: Clinical Notes	S522
Jay P. Sanford	Summary	S523
	SESSION III	
Robert Fekety, Richard O'Connor, and Joseph Silva	Rifampin and Pseudomembranous Colitis	S524
Robert C. Moellering, Jr., and Christine Wennersten	Therapeutic Potential of Rifampin in Enterococcal Infections	S528
William D. Kobasa, Karen L. Kaye, Todd Shapiro, and Donald Kaye	Therapy for Experimental Endocarditis Due to *Staphylococcus epidermidis*	S533
Gordon L. Archer, J. Linda Johnston, Guillermo J. Vazquez, and Hubert B. Haywood III	Efficacy of Antibiotic Combinations Including Rifampin Against Methicillin-Resistant *Staphylococcus epidermidis:* In Vitro and in Vivo Studies	S538
Adolf W. Karchmer, Gordon L. Archer, and William E. Dismukes	Rifampin Treatment of Prosthetic Valve Endocarditis Due to *Staphylococcus epidermidis*	S543
M. P. Glode, R. S. Daum, N. A. Halsey, T. L. Johansen, D. A. Goldmann, D. Ambrosino, E. Boies, and D. M. Granoff	Rifampin Alone and in Combination with Trimethoprim in Chemoprophylaxis for Infections Due to *Haemophilus influenzae* Type b	S549
Robert B. Jones, Geoffrey L. Ridgway, Sandra Boulding, and Kathleen L. Hunley	In Vitro Activity of Rifamycins Alone and in Combination with Other Antibiotics Against *Chlamydia trachomatis*	S556
Julius Schachter	Rifampin in Chlamydial Infections	S562
Frank A. Plummer, Herbert Nsanze, Lourdes J. D'Costa, A. B. Ndugga Maggwa, Yves Girouard, Peter Karasira, W. L. Albritton, and Allan R. Ronald	Short-Course and Single-Dose Antimicrobial Therapy for Chancroid in Kenya: Studies with Rifampin Alone and in Combination with Trimethoprim	S565
W. Brumfitt, Shirley Dixson, and J. M. T. Hamilton-Miller	Use of Rifampin for the Treatment of Urinary Tract Infections	S573
King K. Holmes	Summary	S583
	SESSION IV	
Maria Maduri-Traczewski, Elizabeth G. Szymczak, and Donald A. Goldmann	In Vitro Activity of Penicillin and Rifampin Against Group B Streptococci	S586

W. Michael Scheld	Evaluation of Rifampin and Other Antibiotics Against *Listeria monocytogenes* in Vitro and in Vivo	S593
Roberta Conti and Francesco Parenti	Rifampin Therapy for Brucellosis, Flavobacterium Meningitis, and Cutaneous Leishmaniasis	S600
Ward E. Bullock	Rifampin in the Treatment of Leprosy	S606
Gerald Medoff	Antifungal Action of Rifampin	S614
John R. Graybill and Joan Ahrens	Interaction of Rifampin with Other Antifungal Agents in Experimental Murine Candidiasis	S620
Joel D. Ernst, Michael Rusnak, and Merle A. Sande	Combination Antifungal Chemotherapy for Experimental Disseminated Candidiasis: Lack of Correlation Between in Vitro and in Vivo Observations with Amphotericin B and Rifampin	S626
Edward W. Hook	Summary	S631

Volume 5 • Number 5 • September–October 1983

REVIEW ARTICLES

Edward J. Young	Human Brucellosis	821
Peter Elsbach and Jerrold Weiss	A Reevaluation of the Roles of the O_2-Dependent and O_2-Independent Microbicidal Systems of Phagocytes	843
Peter E. Hohl, H. Preston Holley, Jr., Elena Prevost, Libero Ajello, and Arvind A. Padhye	Infections Due to *Wangiella dermatitidis* in Humans: Report of the First Documented Case from the United States and a Review of the Literature	854
Atef M. Shibl	Effect of Antibiotics on Production of Enzymes and Toxins by Microorganisms	865
Daniel V. Landers and Richard L. Sweet	Tubo-ovarian Abscess: Contemporary Approach to Management	876
David H. Bor, Richard M. Rose, John F. Modlin, Ronald Weintraub, and Gerald H. Friedland	Mediastinitis After Cardiovascular Surgery	885
Edward J. Bottone and Daniel J. Sheehan	*Yersinia enterocolitica:* Guidelines for Serologic Diagnosis of Human Infections	898
Richard D. Pearson, David A. Wheeler, Lee H. Harrison, and H. David Kay	The Immunobiology of Leishmaniasis	907
Carl W. Norden	A Critical Review of Antibiotic Prophylaxis in Orthopedic Surgery	928

SERIAL FEATURES

David I. Grove	Selective Primary Health Care: Strategies for Control of Disease in the Developing World. VII. Filariasis	933

David H. Molyneux	Selective Primary Health Care: Strategies for Control of Disease in the Developing World. VIII. African Trypanosomiasis	945
Frederick C. Robbins and Elena O. Nightingale	Selective Primary Health Care: Strategies for Control of Disease in the Developing World. IX. Poliomyelitis	957
	CLASSICS IN INFECTIOUS DISEASES	
L. Danielson and E. Mann	The First American Account of Cerebrospinal Meningitis	969
	EDITORIAL	
Edward H. Kass	Seduction in a Grand Hotel	973
	CORRESPONDENCE	
Albert E. Yellin, Thomas V. Berne, Peter N. R. Heseltine, and Maria D. Appleman	Cefoperazone for Intraabdominal Infections	975
Ian M. Baird	Reply	975

Volume 5 • Supplement 4 • September–October 1983

	Participants	vi
P. Frederick Sparling, John Swanson, and Milton Puziss	Introduction	S633
P. Frederick Sparling	Lewis W. Wannamaker: A Tribute	S636
	FACTORS AND MECHANISMS OF BACTERIAL VIRULENCE OR PATHOGENICITY	
P. Frederick Sparling	Bacterial Virulence and Pathogenesis: An Overview	S637
Rolf Freter and Garth W. Jones	Models for Studying the Role of Bacterial Attachment in Virulence and Pathogenesis	S647
Johannes van Houte	Bacterial Adherence in the Mouth	S659
Edwin H. Beachey, W. Andrew Simpson, Itzhak Ofek, D. L. Hasty, James B. Dale, and Ellen Whitnack	Attachment of *Streptococcus pyogenes* to Mammalian Cells	S670
John Swanson	Gonococcal Adherence: Selected Topics	S678
Albert M. Collier	Attachment by Mycoplasmas and Its Role in Disease	S685
Doyle J. Evans, Jr. and Dolores G. Evans	Classification of Pathogenic *Escherichia coli* According to Serotype and the Production of Virulence Factors, with Special Reference to Colonization-Factor Antigens	S692

Samuel B. Formal, Thomas L. Hale, and Philippe J. Sansonetti	Invasive Enteric Pathogens	S702
Zell A. McGee, David S. Stephens, Loren H. Hoffman, Walter F. Schlech III, and Robert G. Horn	Mechanisms of Mucosal Invasion by Pathogenic *Neisseria*	S708
Donald E. Woods and Barbara H. Iglewski	Toxins of *Pseudomonas aeruginosa:* New Perspectives	S715
Lewis W. Wannamaker	Streptococcal Toxins	S723
David C. Morrison	Bacterial Endotoxins and Pathogenesis	S733
Robert R. Brubaker	The VWA$^+$ Virulence Factor of Yersiniae: The Molecular Basis of the Attendant Nutritional Requirement for Ca^{++}	S748
Richard A. Finkelstein, Carmen V. Sciortino, and Mark A. McIntosh	Role of Iron in Microbe-Host Interactions	S759
Emil C. Gotschlich	Thoughts on the Evolution of Strategies Used by Bacteria for Evasion of Host Defenses	S778
	HOST RESISTANCE AND DEFENSES	
T. B. Tomasi, Jr.	Mechanisms of Immune Regulation at Mucosal Surfaces	S784
Peter A. Ward and Steven L. Kunkel	Bacterial Virulence and the Inflammatory System	S793
Eric J. Brown, Stephen W. Hosea, and Michael M. Frank	The Role of Antibody and Complement in the Reticuloendothelial Clearance of Pneumococci from the Bloodstream	S797
John K. Spitznagel	Microbial Interactions with Neutrophils	S806
Emil Skamene	Genetic Regulation of Host Resistance to Bacterial Infection	S823

Volume 5 • Number 6 • November–December 1983

	REVIEW ARTICLES	
Stuart P. Adler	Transfusion-associated Cytomegalovirus Infections	977
Thomas H. Weller	Too Few and Too Little: Barricades to the Pursuit of Health	994
Fred Gordin, Cliff Stamler, and John Mills	Pyogenic Psoas Abscesses: Noninvasive Diagnostic Techniques and Review of the Literature	1003
Linda L. Van Etta, Gregory A. Filice, Ronald M. Ferguson, and Dale N. Gerding	*Corynebacterium equi*: A Review of 12 Cases of Human Infection	1012

Mark H. Kaplan, S. Wayne Klein, Jeannemarie McPhee, and Rita G. Harper	Group B Coxsackievirus Infections in Infants Younger than Three Months of Age: A Serious Childhood Illness	1019
John E. McGowan, Jr.	Antimicrobial Resistance in Hospital Organisms and its Relation to Antibiotic Use	1033
Martha H. Tanner and DeVon C. Hale	The Nature of an Infectious Disease Practice in a Community Hospital	1049
Michael G. Rinaldi	Invasive Aspergillosis	1061
Elliot Goldstein	Hydrolytic Enzymes of Alveolar Macrophages	1078
	SERIAL FEATURES	
Adolfo Martínez-Palomo and Manuel Martínez-Báez	Selective Primary Health Care: Strategies for Control of Disease in the Developing World. X. Amebiasis	1093
	CLASSICS IN INFECTIOUS DISEASES	
Walter Reed, James Carroll, A. Agramonte, and Jesse W. Lazear	The Etiology of Yellow Fever: A Preliminary Report	1103
	EDITORIAL	
Karel Raška	Epidemiologic Surveillance in the Control of Infectious Disease	1112
	CORRESPONDENCE	
William L. Krinsky	Does Epizootic Lymphocytic Choriomeningitis Prime the Pump for Epidemic Rickettsialpox?	1118
	NOTICES	1120
	INDEXES TO VOLUME 5	
	Author Index	1121
	Subject Index	1124
	Contents for Volume 5	iii

Volume 5 • Supplement 5 • November–December 1983

	Participants	vi
Jerald C. Sadoff and Jay P. Sanford	Summary of the Symposium	S833
	SESSION I. EPIDEMIOLOGY	
Alan Cross, James R. Allen, John Burke, Georges Ducel, Alan Harris, Joseph John, David Johnson, Michael Lew, Bruce MacMillan, Peter Meers, Radmila Skalova, Richard Wenzel, and James Tenney	Nosocomial Infections Due to *Pseudomonas aeruginosa:* Review of Recent Trends	S837

SESSION II. RESPIRATORY TRACT INFECTIONS

DONALD E. WOODS, DAVID C. STRAUS, W. G. JOHANSON, JR., AND JOE A. BASS — Factors Influencing the Adherence of *Pseudomonas aeruginosa* to Mammalian Buccal Epithelial Cells — S846

JAMES E. PENNINGTON AND GERALD B. PIER — Efficacy of Cell Wall *Pseudomonas aeruginosa* Vaccines for Protection Against Experimental Pneumonia — S852

J. YUZURU HOMMA, CHIYOJI ABE, RYO YANAGAWA, AND HIROSHI NODA — Effectiveness of Immunization with Multicomponent Vaccines in Protection Against Hemorrhagic Pneumonia Due to *Pseudomonas aeruginosa* Infection in Mink — S858

J. W. COSTERTON, J. LAM, K. LAM, AND R. CHAN — The Role of the Microcolony Mode of Growth in the Pathogenesis of *Pseudomonas aeruginosa* Infections — S867

J. R. W. GOVAN, JANET A. M. FYFE, AND N. R. BAKER — Heterogeneity and Reduction in Pulmonary Clearance of Mucoid *Pseudomonas aeruginosa* — S874

EVA A. OMBAKA, ROBERT M. COZENS, AND MICHAEL R. W. BROWN — Influence of Nutrient Limitation of Growth on Stability and Production of Virulence Factors of Mucoid and Nonmucoid Strains of *Pseudomonas aeruginosa* — S880

SESSION III. BURN INFECTIONS

BASIL A. PRUITT, JR., R. B. LINDBERG, W. F. MCMANUS, AND A. D. MASON, JR. — Current Approach to Prevention and Treatment of *Pseudomonas aeruginosa* Infections in Burned Patients — S889

ALBERT T. MCMANUS — Examination of Neutrophil Function in a Rat Model of Decreased Host Resistance Following Burn Trauma — S898

RICHARD A. BECKER, GEORGE M. VAUGHAN, CLEON W. GOODWIN, JR., MICHAEL G. ZIEGLER, CLAUDIA A. ZITZKA, ARTHUR D. MASON, JR., AND BASIL A. PRUITT, JR. — Interaction of Thyroid Hormones and Catecholamines in Severely Burned Patients — S908

IAN ALAN HOLDER — Experimental Studies of the Pathogenesis of Infections Due to *Pseudomonas aeruginosa:* Effect of Treatment with Protease Inhibitors — S914

ELIZABETH A. ROE AND RODERICK J. JONES — Immunization of Burned Patients Against *Pseudomonas aeruginosa* Infection at Safdarjang Hospital, New Delhi — S922

SESSION IV. OCULAR INFECTIONS

ARNOLD S. KREGER — Pathogenesis of *Pseudomonas aeruginosa* Ocular Diseases — S931

RICHARD S. BERK AND LINDA D. HAZLETT — Further Studies on the Genetic Control of Murine Corneal Response to *Pseudomonas aeruginosa* — S936

SESSION V. SURFACE ANTIGENS

STEPHEN G. WILKINSON — Composition and Structure of Lipopolysaccharides from *Pseudomonas aeruginosa* — S941

GERALD B. PIER — Immunochemistry of *Pseudomonas aeruginosa* Lipopolysaccharides and High-Molecular-Weight Polysaccharides — S950

Richard B. Markham and Gerald B. Pier	Immunologic Basis for Mouse Protection Provided by High-Molecular-Weight Polysaccharide from Immunotype 1 *Pseudomonas aeruginosa*	S957
Bernard R. Tegtmeier and Burton R. Andersen	Mechanisms of Lipopolysaccharide-Induced Protection Against Pseudomonas Sepsis in Granulocytopenic Mice	S963
Pasquale F. Bartell	Determinants of the Biologic Activity of Surface Slime in Experimental *Pseudomonas aeruginosa* Infections	S971
	SESSION VI. EXTRACELLULAR PRODUCTS	
Matthew Pollack	The Role of Exotoxin A in Pseudomonas Disease and Immunity	S979
D. FitzGerald, R. E. Morris, and C. B. Saelinger	Inhibition of the Activity of Pseudomonas Toxin by Methylamine	S985
Stanley J. Cryz, Jr. and Barbara H. Iglewski	Toxoids of *Pseudomonas aeruginosa* Toxin A: Production by Chemical and Genetic Means	S992
Bengt Wretlind and Olgerts R. Pavlovskis	*Pseudomonas aeruginosa* Elastase and Its Role in Pseudomonas Infections	S998